The most promising drug with GLP-1R/GIPR dual agonist effects is Tripeptide (LY3298176), developed by Eli Lilly and Company, which the Food and Drug Administration (FDA) has approved for treating type II diabetes and obesity16. Here, GLP1R is linked to type 2 diabetes mellitus.